Magnitude Biosciences, the world’s leading C. elegans Contract Research Organisation (CRO) and commercial lab, is on an amazing journey. When we started in 2018, the potential of C. elegans to address research challenges was largely unknown to biotechs and the R&D teams of large manufacturing, health products and consumer goods companies. Now, in 2021, we are enabling:
- Drug discoverers impress their investors with trustworthy and reproducible data on the impact of their compounds on health and quality of life
- Pharmaceutical companies accelerate the development of game-changing therapeutics in the areas of ageing, microbiome and neurodegeneration
- Pharmaceutical companies accelerate the development of game-changing therapeutics in the areas of ageing, microbiome and neurodegeneration
- Fortune 500 consumer goods companies keep their customers and the environment safe by measuring the toxicity of the compounds going into their products much faster and more cost-effectively than using rodent or other mammalian models
- Health product and nutrition companies deliver their promises to help their customers live better lives by producing evidence that their compounds actually make a positive difference to the health of whole organisms
What our customers say it’s like to work with us
In order to bring our expertise and specialist services to an even wider group of industry innovators, we have in April 2021 launched a new website that better explains how we help accelerate research projects.